The role of temozolomide as adjuvant therapy in glioblastoma management: a systematic review and meta-analysis.
Authors:
- Made Agus Mahendra InggasMIMade Agus Mahendra Inggas
- Utsav PatelUPUtsav Patel
- Jeremiah Hilkiah WijayaJeremiah Hilkiah Wijaya
- Nina OtinashviliNONina Otinashvili
- Abhay Krishnan IyerAIAbhay Krishnan Iyer
- Tawfiq TurjmanTTTawfiq Turjman
- Surbhi DadwalSDSurbhi Dadwal
- Mari GadaeviMGMari Gadaevi
- Azada IsmayilovaAIAzada Ismayilova
- Shiva Jashwanth GaddamSGShiva Jashwanth Gaddam
- Prakriti AryaPAPrakriti Arya
Open Access
- 5 March 2025
- journal article
- review article
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-8
Abstract
The persistent challenge of temozolomide (TMZ) resistance and the eventual recurrence of tumors underscore the need for ongoing research and the development of novel therapeutic strategies. We aim to consolidate existing evidence related to the safety and efficacy of TMZ as adjuvant therapy to radiotherapy (RT). Various electronic platforms were used to conduct a systematic literature review, including PubMed, Europe PMC, SCOPUS, and clinicaltrials.gov. The approach aimed to identify all pertinent studies published up to July 25, 2024. The search incorporated terms such as “glioblastoma,” “temozolomide,” “monotherapy,” and “adjuvant” alongside relevant Medical Subject Headings (MeSH). The key metrics were overall and progression-free survival, while secondary measures concentrated on treatment-related adverse effects, notably hematological issues like anemia, leukopenia, thrombocytopenia, and neutropenia. The overall effect estimates from the forest plots show significant differences favoring TMZ + RT over RT alone. The HR for overall survival is 0.64 (95% CI: 0.58, 0.71), showing a considerable improvement with TMZ + RT. Progression-free survival shows a HR of 0.51 (95% CI: 0.45, 0.58), also demonstrating a significant benefit for TMZ + RT. Combining TMZ with RT generally leads to better overall and progression-free survival outcomes compared to RT alone. However, the two treatment groups have similar toxicity.Keywords
This publication has 22 references indexed in Scilit:
- Radiotherapy Plus Concurrent or Sequential Temozolomide for Glioblastoma in the Elderly: A Meta-AnalysisPLOS ONE, 2013
- Efficacy of concomitant and adjuvant temozolomide in glioblastoma treatment. A multicentre randomized studyNeurologia i Neurochirurgia Polska, 2013
- Concomitant temozolomide and radiotherapy versus radiotherapy alone for treatment of newly diagnosed glioblastoma multiforme.2011
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Randomized Study of Postoperative Radiotherapy and Simultaneous Temozolomide without Adjuvant Chemotherapy for GlioblastomaStrahlentherapie und Onkologie, 2008
- The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastomaJournal of Neuro-Oncology, 2008
- Food and Drug Administration Drug Approval Summary: Temozolomide Plus Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma MultiformeClinical Cancer Research, 2005
- Randomized Phase II Study of Temozolomide and Radiotherapy Compared With Radiotherapy Alone in Newly Diagnosed Glioblastoma MultiformeJournal of Clinical Oncology, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Individual patient‐ versus group‐level data meta‐regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly headStatistics in Medicine, 2002